Abstract
Purpose
Women with breast cancer frequently use antidepressants; however, questions about the effect of these medications on breast cancer recurrence remain.
Methods
We identified 4,216 women ≥18 years with an incident stage I or II breast cancer diagnosed between 1990 and 2008 in a mixed-model healthcare delivery system linked to a cancer registry. Recurrences were ascertained from chart review. Medication exposures were extracted from electronic pharmacy records. We used multivariable Cox proportional hazards models to estimate hazard ratios (HR) and 95 % confidence intervals (CI) to assess the association between antidepressant use and breast cancer recurrence and mortality. We also conducted analyses restricted to tamoxifen users.
Results
Antidepressants overall, tricyclic antidepressants, and selective serotonin reuptake inhibitors were not associated with risk of breast cancer recurrence or mortality. Women taking paroxetine only (adjusted HR: 1.66; 95 % CI 1.02, 2.71) and trazodone only (adjusted HR: 1.76; 95 % CI 1.06, 2.92), but not fluoxetine only (adjusted HR: 0.92; 95 % CI 0.55, 1.53), had higher recurrence risks than antidepressant nonusers. There was some suggestion of an increased recurrence risk with concurrent paroxetine and tamoxifen use compared with users of tamoxifen only (adjusted HR: 1.49; 95 % CI 0.79, 2.83).
Conclusions
In general, antidepressants did not appear increase risk of breast cancer recurrence, though there were some suggested increases in risk that warrant further investigation in other datasets. Our results combined systematically and quantitatively with results from other studies may be useful for patients and providers making decisions about antidepressant use after breast cancer diagnosis.
Similar content being viewed by others
References
Chubak J, Buist DS, Boudreau DM, Rossing MA, Lumley T, Weiss NS (2008) Breast cancer recurrence risk in relation to antidepressant use after diagnosis. Breast Cancer Res Treat 112:123–132. doi:10.1007/s10549-007-9828-9
Dusetzina SB, Alexander GC, Freedman RA, Huskamp HA, Keating NL (2012) Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004–2010. Breast Cancer Res Treat. doi:10.1007/s10549-012-2330-z
Fisch MJ, Zhao F, Manola J, Miller AH, Pirl WF, Wagner LI (2015) Patterns and predictors of antidepressant use in ambulatory cancer patients with common solid tumors. Psycho Oncol 24:523–532. doi:10.1002/pon.3606
Burstein HJ, Temin S, Anderson H et al (2014) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol 32:2255–2269. doi:10.1200/JCO.2013.54.2258
Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758–1764
Cronin-Fenton DP, Lash TL (2011) Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes. Expert Rev Clin Pharmacol 4:363–377. doi:10.1586/ecp.11.18
Jin Y, Desta Z, Stearns V et al (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30–39
Desmarais JE, Looper KJ (2009) Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry 70:1688–1697. doi:10.4088/JCP.08r04856blu
Rae JM, Drury S, Hayes DF et al (2012) CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Nat Cancer Inst 104:452–460. doi:10.1093/jnci/djs126
Regan MM, Leyland-Jones B, Bouzyk M et al (2012) CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 Trial. J Nat Cancer Inst 104:441–451. doi:10.1093/jnci/djs125
Lum DW, Perel P, Hingorani AD, Holmes MV (2013) CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis. PLoS ONE 8:e76648. doi:10.1371/journal.pone.0076648
Province MA, Goetz MP, Brauch H et al (2014) CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther [Articles] 95:216–227. doi:10.1038/clpt.2013.186
Mwinyi J, Vokinger K, Jetter A, Breitenstein U, Hiller C, Kullak-Ublick GA, Trojan A (2014) Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifen therapy. Cancer Chemother Pharmacol 73:1181–1188. doi:10.1007/s00280-014-2453-5
Brauch H, Schroth W, Goetz MP, Mürdter TE, Winter S, Ingle JN, Schwab M, Eichelbaum M (2013) Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol 31:176–180. doi: 10.1200/jco.2012.44.6625
Kelly CM, Pritchard KI (2012) CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned. J Nat Cancer Inst 104:427–428. doi:10.1093/jnci/djs139
Kelly CM, Pritchard KI (2012) Response. J Nat Cancer Inst 104:1268. doi:10.1093/jnci/djs303
Berry D (2013) CYP2D6 genotyping and the use of tamoxifen in breast cancer. J Nat Cancer Inst 105:1267–1269. doi:10.1093/jnci/djt221
Pharoah PD, Abraham J, Caldas C (2012) Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The Breast International Group 1-98 Trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst. doi:10.1093/jnci/djs312
Berry DA (2014) CYP2D6 genotype and adjuvant tamoxifen. Clin Pharmacol Ther [Point/Counterpoint] 96:138–140. doi:10.1038/clpt.2014.96
U.S. Food and Drug Administration. Safety: Paxil CR (paroxetine hydrochloride) Controlled-Release Tablets October 2008. Silver Spring, MD: U.S. Food and Drug Administration; 2008. Updated September 24, 2013; cited 2014 December 28. http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/ucm122147.htm
U.S. Food and Drug Administration. Safety: Paxil (paroxetine HCl) tablets, oral solution and Paxil CR tablets. Silver Spring, MD: U.S. Food and Drug Administration; 2011. Updated August 11, 2011; cited 2014 December 28. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm233693.htm
Ahern TP, Pedersen L, Cronin-Fenton DP, Sørensen HT, Lash TL (2009) No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications. Cancer Epidemiol Biomarkers Prev 18:2562–2564. doi:10.1158/1055-9965.epi-09-0516
Lash TL, Pedersen L, Cronin-Fenton D et al (2008) Tamoxifen’s protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. Br J Cancer 99:616–621
Lash TL, Rosenberg CL (2010) Evidence and practice regarding the role for CYP2D6 inhibition in decisions about tamoxifen therapy. J Clin Oncol 28:1273–1275. doi:10.1200/JCO.2009.26.7906
Siegelmann-Danieli N, Kurnik D, Lomnicky Y, Vesterman-Landes J, Katzir I, Bialik M, Loebstein R (2011) Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen. Breast Cancer Res Treat 125:505–510. doi:10.1007/s10549-010-1008-7
Lehmann D, Nelsen J, Ramanath V, Newman N, Duggan D, Smith A (2004) Lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition. J Clin Pharmacol 44:861–865
Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI, Austin PC, Paszat LF (2010) Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 340:c693. doi:10.1136/bmj.c693
Dezentje VO, van Blijderveen NJC, Gelderblom H, Putter H, van Herk-Sukel MPP, Casparie MK, Egberts ACG, Nortier JWR, Guchelaar H-J (2010) Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol 28:2423–2429. doi:10.1200/jco.2009.25.0894
Wernli KJ, Hampton JM, Trentham-Dietz A, Newcomb PA (2011) Use of antidepressants and NSAIDs in relation to mortality in long-term breast cancer survivors. Pharmacoepidemiol Drug Saf 20:131–137. doi:10.1002/pds.2064
Azoulay L, Dell’Aniello S, Huiart L, du Fort G, Suissa S (2011) Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence. Breast Cancer Res Treat 126:695–703. doi:10.1007/s10549-010-1162-y
Lash TL, Cronin-Fenton D, Ahern TP et al (2010) Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. Acta Oncol. doi:10.3109/02841860903575273
Boudreau DM, Yu O, Chubak J, Wirtz HS, Bowles EJ, Fujii M, Buist DS (2014) Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer. Breast Cancer Res Treat 144:405–416. doi:10.1007/s10549-014-2870-5
Wirtz HS, Buist DS, Gralow JR et al (2013) Frequent antibiotic use and second breast cancer events. Cancer Epidemiol Biomarkers Prev 22:1588–1599. doi:10.1158/1055-9965.EPI-13-0454
Geiger AM, Thwin SS, Lash TL et al (2007) Recurrences and second primary breast cancers in older women with initial early-stage disease. Cancer 109:966–974
Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613–619. doi:10.1016/0895-4356(92)90133-8
Boudreau DM, Doescher MP, Saver BG, Jackson JE, Fishman PA (2005) Reliability of Group Health Cooperative automated pharmacy data by drug benefit status. Pharmacoepidemiol Drug Saf 14:877–884
Saunders KW, Davis RL, Stergachis A (2005) Group Health Cooperative. In: Strom BL (ed) Pharmacoepidemiology, 4th edn. Wiley, Chichester, pp 223–239
Smith NL, Heckbert SR, Lemaitre RN, Reiner AP, Lumley T, Weiss NS, Larson EB, Rosendaal FR, Psaty BM (2004) Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA 292:1581–1587
Varadhan R, Weiss CO, Segal JB, Wu AW, Scharfstein D, Boyd C (2010) Evaluating health outcomes in the presence of competing risks: a review of statistical methods and clinical applications. Med Care 48(6) Supplement:S96–S105
Chubak J, Yu O, Buist DS, Wirtz HS, Boudreau DM (2013) Time scale in follow-up studies: considering disease prognosis. Epidemiology 24:628–629. doi:10.1097/EDE.0b013e3182961708
Greene FL, Page DL, Fleming ID, Fritz AG, Balch C, Haller DG, Morrow M (eds) (2002) AJCC cancer staging manual, 6th edn. Springer, New York
Phipps AI, Ichikawa L, Bowles EJA, Carney PA, Kerlikowske K, Miglioretti DL, Buist DSM (2010) Defining menopausal status in epidemiologic studies: a comparison of multiple approaches and their effects on breast cancer rates. Maturitas 67:60–66. doi:10.1016/j.maturitas.2010.04.015
Chubak J, Boudreau DM, Wirtz HS, McKnight B, Weiss NS (2013) Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival. J Natl Cancer Inst 105:1456–1462. doi:10.1093/jnci/djt211
Wu AHB, Lorizio W, Tchu S et al (2012) Estimation of tamoxifen metabolite concentrations in the blood of breast cancer patients through CYP2D6 genotype activity score. Breast Cancer Res Treat 133:677–683. doi:10.1007/s10549-012-1963-2
Bertisch SM, Herzig SJ, Winkelman JW, Buettner C (2014) National use of prescription medications for insomnia: NHANES 1999-2010. Sleep 37:343–349. doi:10.5665/sleep.3410
Acknowledgments
The authors would like to thank Dr. Heidi Wirtz for helpful discussions and input on preliminary analyses.
Funding
This study was funded by the National Cancer Institute at the National Institutes of Health, Award Number R01CA120562 to Denise M. Boudreau. Part of the data collection was supported by a grant from the National Cancer Institute: U01CA63731, PI: Buist. The collection of cancer incidence data used in this study was supported by the Cancer Surveillance System of the Fred Hutchinson Cancer Research Center, which is funded by Contract No. N01-CN-67009 and N01-PC-35142 from the Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute with additional support from the Fred Hutchinson Cancer Research Center and the State of Washington. Funders did not participate in the design, data collection, manuscript drafting, or decision to submit the manuscript for publication.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Ms. Yu has received funding from unrelated research grants awarded to Group Health Research Institute from Amgen and Bayer. Dr. Boudreau has received funding from unrelated research grants awarded to Group Health Research Institute from Amgen, Sanofi Aventis, and Johnson & Johnson.
Ethical approval
For this type of study, formal consent is not required.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Chubak, J., Bowles, E.J.A., Yu, O. et al. Breast cancer recurrence in relation to antidepressant use. Cancer Causes Control 27, 125–136 (2016). https://doi.org/10.1007/s10552-015-0689-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10552-015-0689-y